(Q37987985)

26 August 2017

title

Lurasidone for schizophrenia: what's different? (English)

1 reference

26 August 2017

0 references

1 reference

ChEBI release 2020-05-28

2

1 reference

26 August 2017

Joshua T Kantrowitz

1

1 reference

26 August 2017

publication date

1 March 2012

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

26 August 2017

published in

1 reference

26 August 2017

volume

12

1 reference

26 August 2017

issue

3

1 reference

26 August 2017

page(s)

265-273

1 reference

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

26 August 2017

cites work

1 reference

Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models

21 January 2018

1 reference

Risk factors for schizophrenia--all roads lead to dopamine

21 January 2018

1 reference

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment

21 January 2018

1 reference

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

21 January 2018

1 reference

A meta-analysis of the efficacy of second-generation antipsychotics

21 January 2018

1 reference

Akathisia: an updated review focusing on second-generation antipsychotics

21 January 2018

1 reference

Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics

21 January 2018

1 reference

Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic

21 January 2018

1 reference

Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic

21 January 2018

1 reference

Clinical potential of lurasidone in the management of schizophrenia

21 January 2018

1 reference

Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder

21 January 2018

1 reference

Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity

21 January 2018

1 reference

Pharmacokinetics and metabolism update for some recent antipsychotics

21 January 2018

1 reference

Lurasidone: a new drug in development for schizophrenia

21 January 2018

1 reference

The dopamine hypothesis of schizophrenia: version III--the final common pathway

21 January 2018

1 reference

The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats

21 January 2018

1 reference

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

21 January 2018

1 reference

Comment on the potential utility of the new atypical antipsychotic lurasidone in the geriatric population

21 January 2018

1 reference

Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone

21 January 2018

1 reference

A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP)

21 January 2018

1 reference

Psychiatric stress testing: novel strategy for translational psychopharmacology

21 January 2018

1 reference

Premorbid IQ in schizophrenia: a meta-analytic review

21 January 2018

1 reference

Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?

21 January 2018

1 reference

The novel antipsychotic drug lurasidone enhances N-methyl-D-aspartate receptor-mediated synaptic responses

21 January 2018

1 reference

N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?

21 January 2018

1 reference

The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.

21 January 2018

1 reference

The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity

21 January 2018

1 reference

A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia.

21 January 2018

1 reference

Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making

21 January 2018

1 reference

Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial

21 January 2018

1 reference

Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties.

21 January 2018

1 reference

A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder

21 January 2018

1 reference

Olanzapine: review of safety 2008

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERN.12.7

1 reference

26 August 2017

1 reference